Prestige Brands Holdings Inc (PBH) Stock
Key stats
- Market cap
- $2.09B
- Price / Earnings ratio
- 13.7x
- EPS (TTM)
- $3.25
- Volume
- Loading
- 52-week high
- $71.07
- 52-week low
- $41.77
Source: third-party data provider, as of November 13, 2026
Compare with PBH
Recent news

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
PBH

Best Value Stocks to Buy for October 1st
Best Value Stocks to Buy for October 1st
PBH

PBH vs. NEOG: Which Stock Is the Better Value Option?
PBH vs. NEOG: Which Stock Is the Better Value Option?
PBH

Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow
Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow
PBH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.15
- MACD 12/26/9
- -0.88
- EMA 9 of MACD
- -0.30
- MACD histogram
- -0.58
- SMA 50
- $47.68
- Price below SMA 50
- EMA 50
- $47.95
- Price below EMA 50
- SMA 200
- $53.32
- Price below SMA 200
- EMA 200
- $53.25
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
No data available
Source: third-party data provider
Latest news

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
PBH

Best Value Stocks to Buy for October 1st
Best Value Stocks to Buy for October 1st
PBH

PBH vs. NEOG: Which Stock Is the Better Value Option?
PBH vs. NEOG: Which Stock Is the Better Value Option?
PBH

Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow
Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow
PBH

PBH or NEOG: Which Is the Better Value Stock Right Now?
PBH or NEOG: Which Is the Better Value Stock Right Now?
PBH

Is This the Right Time to Add PBH Stock to Your Portfolio?
Is This the Right Time to Add PBH Stock to Your Portfolio?
PBH

PBH vs. SYK: Which Stock Is the Better Value Option?
PBH vs. SYK: Which Stock Is the Better Value Option?
PBH

Here's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock
Here's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock
PBH

PBH or SYK: Which Is the Better Value Stock Right Now?
PBH or SYK: Which Is the Better Value Stock Right Now?
PBH

Premium Brands Q2 Earnings Call Highlights
Premium Brands Q2 Earnings Call Highlights
PBH
News tone: automated (AI) classification of the article's content, not a price prediction.
About Prestige Brands Holdings Inc
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ronald M. Lombardi CPA | Chairman, President & CEO | 1964 |
| Ms. Christine Sacco CPA | CFO & COO | 1976 |
| Mr. William C. P'Pool J.D. | Senior VP, General Counsel & Corporate Secretary | 1965 |
| Mr. Adel Mekhail | Executive Vice President of Marketing & Sales | 1961 |
| Mr. Philip David Terpolilli C.F.A. | Director of Investor Relations | — |
| Dean Siegal | Director of Communications | — |
| Mr. Jose Luis Rosado | Senior Vice President of Quality & Regulatory Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.15
- MACD 12/26/9
- -0.88
- EMA 9 of MACD
- -0.30
- MACD histogram
- -0.58
- SMA 50
- $47.68
- Price below SMA 50
- EMA 50
- $47.95
- Price below EMA 50
- SMA 200
- $53.32
- Price below SMA 200
- EMA 200
- $53.25
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $70.00
- Average
- $70.00
- High
- $70.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.7 | +6.2 | ||||||||||
| 2022 | -6.9 | +5.1 | -11.2 | +3.0 | +2.5 | +5.5 | +1.2 | -17.2 | -2.8 | +9.5 | +10.9 | -0.3 |
| 2023 | +3.6 | -9.0 | +3.5 | -3.0 | -8.4 | +4.8 | +10.2 | -10.8 | -2.0 | +3.7 | -3.6 | +4.5 |
| 2024 | -0.7 | +11.3 | +3.5 | +0.1 | -9.6 | +7.7 | +3.8 | |||||
| 2026 | +1.3 | -2.4 | -13.7 | +2.9 | +4.3 | -0.3 | -12.9 | +9.6 | -11.2 |




